25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Akero Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Akero Therapeutics Inc together

I guess you are interested in Akero Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akero Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akero Therapeutics Inc

I send you an email if I find something interesting about Akero Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Akero Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Akero Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$4.83
When do you have the money?
1 year
How often do you get paid?
10.7%

What is your share worth?

Current worth
$10.58
Expected worth in 1 year
$12.80
How sure are you?
32.1%

+ What do you gain per year?

Total Gains per Share
$7.05
Return On Investment
22.8%

For what price can you sell your share?

Current Price per Share
$30.92
Expected price per share
$26.46 - $35.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akero Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$30.92
Intrinsic Value Per Share
$-52.61 - $-62.49
Total Value Per Share
$-42.03 - $-51.91

2.2. Growth of Akero Therapeutics Inc (5 min.)




Is Akero Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$738.3m$458.1m$271.3m37.2%

How much money is Akero Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$59.3m-$28.6m-$30.6m-51.7%
Net Profit Margin-4,857.9%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Akero Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#87 / 949

Most Revenue
#688 / 949

Most Profit
#859 / 949

Most Efficient
#839 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akero Therapeutics Inc?

Welcome investor! Akero Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Akero Therapeutics Inc.

First you should know what it really means to hold a share of Akero Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Akero Therapeutics Inc is $30.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akero Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akero Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.58. Based on the TTM, the Book Value Change Per Share is $0.56 per quarter. Based on the YOY, the Book Value Change Per Share is $0.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $1.21 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akero Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.04-3.4%-0.85-2.7%-0.43-1.4%-0.46-1.5%-0.39-1.2%
Usd Book Value Change Per Share-0.86-2.8%0.561.8%0.862.8%0.431.4%0.381.2%
Usd Dividend Per Share0.000.0%1.213.9%1.213.9%0.481.6%0.341.1%
Usd Total Gains Per Share-0.86-2.8%1.765.7%2.076.7%0.912.9%0.722.3%
Usd Price Per Share28.69-25.19-47.58-28.55-21.89-
Price to Earnings Ratio-6.89--7.46--28.95--18.84--16.02-
Price-to-Total Gains Ratio-33.52--14.05--115.84--48.05--47.80-
Price to Book Ratio2.71-2.47-7.94-7.41-5.99-
Price-to-Total Gains Ratio-33.52--14.05--115.84--48.05--47.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.92
Number of shares32
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.210.48
Usd Book Value Change Per Share0.560.43
Usd Total Gains Per Share1.760.91
Gains per Quarter (32 shares)56.4029.09
Gains per Year (32 shares)225.58116.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1154712166255106
2309142442124109222
3463213668185164338
4618285894247218454
57723561120309273570
69274271346371327686
710814981572433382802
812355691798494436918
9139064020245564911034
10154471122506185461150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.028.00.00.0%0.028.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.017.03.028.6%8.017.03.028.6%
Dividend per Share1.00.03.025.0%3.00.09.025.0%3.00.017.015.0%3.00.025.010.7%3.00.025.010.7%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%6.014.00.030.0%9.016.03.032.1%9.016.03.032.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akero Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.8560.556-254%0.858-200%0.426-301%0.378-327%
Book Value Per Share--10.57810.451+1%6.563+61%5.099+107%3.808+178%
Current Ratio--17.25325.384-32%22.367-23%18.178-5%17.3390%
Debt To Asset Ratio--0.0970.081+20%0.090+8%0.090+7%0.175-45%
Debt To Equity Ratio--0.1070.088+22%0.099+8%0.101+6%0.076+41%
Dividend Per Share---1.207-100%1.208-100%0.483-100%0.345-100%
Enterprise Value--2640564048.0002426732598.250+9%3750420684.000-30%2327050909.850+13%2262025258.045+17%
Eps---1.042-0.850-18%-0.428-59%-0.459-56%-0.385-63%
Ev To Ebitda Ratio---8.080-10.243+27%-33.205+311%-21.371+165%-22.865+183%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---1.009-0.758-25%-0.438-57%-0.403-60%-0.303-70%
Free Cash Flow To Equity Per Share---0.9650.568-270%0.836-215%0.444-317%0.431-324%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---62.488--------
Intrinsic Value_10Y_min---52.606--------
Intrinsic Value_1Y_max---2.657--------
Intrinsic Value_1Y_min---2.607--------
Intrinsic Value_3Y_max---10.729--------
Intrinsic Value_3Y_min---10.188--------
Intrinsic Value_5Y_max---22.115--------
Intrinsic Value_5Y_min---20.290--------
Market Cap2158191264.000+7%2002539048.0001758241848.000+14%3321220434.000-40%1992784609.800+0%1527867095.571+31%
Net Profit Margin----48.5790%-0%-9.7160%-6.9400%
Operating Margin----47.7900%-0%-9.5580%-6.8270%
Operating Ratio---54.466-100%-0%10.893-100%7.781-100%
Pb Ratio2.923+7%2.7122.473+10%7.943-66%7.413-63%5.992-55%
Pe Ratio-7.421-8%-6.886-7.461+8%-28.946+320%-18.841+174%-16.020+133%
Price Per Share30.920+7%28.69025.190+14%47.583-40%28.550+0%21.889+31%
Price To Free Cash Flow Ratio-7.661-8%-7.109-8.789+24%-29.684+318%-21.562+203%-18.717+163%
Price To Total Gains Ratio-36.125-8%-33.520-14.048-58%-115.845+246%-48.046+43%-47.804+43%
Quick Ratio--25.83537.257-31%29.402-12%24.281+6%21.550+20%
Return On Assets---0.089-0.077-14%-0.058-34%-0.096+8%-1.256+1312%
Return On Equity---0.098-0.084-15%-0.064-35%-0.107+8%-0.084-14%
Total Gains Per Share---0.8561.762-149%2.066-141%0.909-194%0.723-218%
Usd Book Value--738325000.000729487750.250+1%458119750.000+61%355930850.050+107%265781321.464+178%
Usd Book Value Change Per Share---0.8560.556-254%0.858-200%0.426-301%0.378-327%
Usd Book Value Per Share--10.57810.451+1%6.563+61%5.099+107%3.808+178%
Usd Dividend Per Share---1.207-100%1.208-100%0.483-100%0.345-100%
Usd Eps---1.042-0.850-18%-0.428-59%-0.459-56%-0.385-63%
Usd Free Cash Flow---70424000.000-52911000.000-25%-30562000.000-57%-28152000.000-60%-21167762.964-70%
Usd Free Cash Flow Per Share---1.009-0.758-25%-0.438-57%-0.403-60%-0.303-70%
Usd Free Cash Flow To Equity Per Share---0.9650.568-270%0.836-215%0.444-317%0.431-324%
Usd Market Cap2158191264.000+7%2002539048.0001758241848.000+14%3321220434.000-40%1992784609.800+0%1527867095.571+31%
Usd Price Per Share30.920+7%28.69025.190+14%47.583-40%28.550+0%21.889+31%
Usd Profit---72705000.000-59305500.000-18%-28648250.000-61%-31790650.000-56%-26665389.607-63%
Usd Revenue---71000.000-100%-0%14200.000-100%10142.857-100%
Usd Total Gains Per Share---0.8561.762-149%2.066-141%0.909-194%0.723-218%
 EOD+5 -3MRQTTM+9 -27YOY+7 -265Y+14 -2210Y+14 -22

3.3 Fundamental Score

Let's check the fundamental score of Akero Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.421
Price to Book Ratio (EOD)Between0-12.923
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than125.835
Current Ratio (MRQ)Greater than117.253
Debt to Asset Ratio (MRQ)Less than10.097
Debt to Equity Ratio (MRQ)Less than10.107
Return on Equity (MRQ)Greater than0.15-0.098
Return on Assets (MRQ)Greater than0.05-0.089
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Akero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.794
Ma 20Greater thanMa 5031.744
Ma 50Greater thanMa 10030.511
Ma 100Greater thanMa 20028.439
OpenGreater thanClose30.770
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Akero Therapeutics Inc

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-12-05 11:51:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akero Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akero Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,857.9%+4,857.9%
TTM-4,857.9%YOY--4,857.9%
TTM-4,857.9%5Y-971.6%-3,886.3%
5Y-971.6%10Y-694.0%-277.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM-4,857.9%-221.4%-4,636.5%
YOY--210.0%+210.0%
5Y-971.6%-342.2%-629.4%
10Y-694.0%-464.5%-229.5%
4.3.1.2. Return on Assets

Shows how efficient Akero Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • -8.9% Return on Assets means that Akero Therapeutics Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akero Therapeutics Inc:

  • The MRQ is -8.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.9%TTM-7.7%-1.2%
TTM-7.7%YOY-5.8%-1.8%
TTM-7.7%5Y-9.6%+1.9%
5Y-9.6%10Y-125.6%+116.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.9%-11.3%+2.4%
TTM-7.7%-11.7%+4.0%
YOY-5.8%-11.3%+5.5%
5Y-9.6%-12.7%+3.1%
10Y-125.6%-14.1%-111.5%
4.3.1.3. Return on Equity

Shows how efficient Akero Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • -9.8% Return on Equity means Akero Therapeutics Inc generated $-0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akero Therapeutics Inc:

  • The MRQ is -9.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.8%TTM-8.4%-1.5%
TTM-8.4%YOY-6.4%-1.9%
TTM-8.4%5Y-10.7%+2.3%
5Y-10.7%10Y-8.4%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.8%-14.2%+4.4%
TTM-8.4%-15.9%+7.5%
YOY-6.4%-14.3%+7.9%
5Y-10.7%-18.5%+7.8%
10Y-8.4%-19.3%+10.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akero Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akero Therapeutics Inc is operating .

  • Measures how much profit Akero Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akero Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,779.0%+4,779.0%
TTM-4,779.0%YOY--4,779.0%
TTM-4,779.0%5Y-955.8%-3,823.2%
5Y-955.8%10Y-682.7%-273.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-4,779.0%-310.7%-4,468.3%
YOY--223.5%+223.5%
5Y-955.8%-387.1%-568.7%
10Y-682.7%-498.5%-184.2%
4.3.2.2. Operating Ratio

Measures how efficient Akero Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM54.466-54.466
TTM54.466YOY-+54.466
TTM54.4665Y10.893+43.573
5Y10.89310Y7.781+3.112
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM54.4663.253+51.213
YOY-3.298-3.298
5Y10.8934.788+6.105
10Y7.7816.494+1.287
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akero Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akero Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 17.25 means the company has $17.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 17.253. The company is very able to pay all its short-term debts. +2
  • The TTM is 25.384. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.253TTM25.384-8.131
TTM25.384YOY22.367+3.017
TTM25.3845Y18.178+7.206
5Y18.17810Y17.339+0.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2533.637+13.616
TTM25.3843.890+21.494
YOY22.3674.666+17.701
5Y18.1785.953+12.225
10Y17.3396.277+11.062
4.4.3.2. Quick Ratio

Measures if Akero Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 25.84 means the company can pay off $25.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 25.835. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 37.257. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.835TTM37.257-11.421
TTM37.257YOY29.402+7.855
TTM37.2575Y24.281+12.975
5Y24.28110Y21.550+2.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.8353.086+22.749
TTM37.2573.451+33.806
YOY29.4024.456+24.946
5Y24.2815.931+18.350
10Y21.5506.436+15.114
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akero Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akero Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akero Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Akero Therapeutics Inc assets are financed with 9.7% credit (debt) and the remaining percentage (100% - 9.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.097. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.081. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.097TTM0.081+0.016
TTM0.081YOY0.090-0.009
TTM0.0815Y0.090-0.009
5Y0.09010Y0.175-0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0970.350-0.253
TTM0.0810.344-0.263
YOY0.0900.310-0.220
5Y0.0900.365-0.275
10Y0.1750.382-0.207
4.5.4.2. Debt to Equity Ratio

Measures if Akero Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.7% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.107. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.088. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.107TTM0.088+0.019
TTM0.088YOY0.099-0.011
TTM0.0885Y0.101-0.013
5Y0.10110Y0.076+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1070.394-0.287
TTM0.0880.432-0.344
YOY0.0990.380-0.281
5Y0.1010.451-0.350
10Y0.0760.490-0.414
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akero Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -6.89 means the investor is paying $-6.89 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akero Therapeutics Inc:

  • The EOD is -7.421. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.886. Based on the earnings, the company is expensive. -2
  • The TTM is -7.461. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.421MRQ-6.886-0.535
MRQ-6.886TTM-7.461+0.575
TTM-7.461YOY-28.946+21.485
TTM-7.4615Y-18.841+11.380
5Y-18.84110Y-16.020-2.820
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.421-2.253-5.168
MRQ-6.886-2.411-4.475
TTM-7.461-3.149-4.312
YOY-28.946-3.274-25.672
5Y-18.841-6.143-12.698
10Y-16.020-6.785-9.235
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akero Therapeutics Inc:

  • The EOD is -7.661. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.109. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.789. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.661MRQ-7.109-0.553
MRQ-7.109TTM-8.789+1.680
TTM-8.789YOY-29.684+20.894
TTM-8.7895Y-21.562+12.772
5Y-21.56210Y-18.717-2.845
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.661-3.009-4.652
MRQ-7.109-3.259-3.850
TTM-8.789-3.730-5.059
YOY-29.684-4.574-25.110
5Y-21.562-8.371-13.191
10Y-18.717-9.287-9.430
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akero Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.71 means the investor is paying $2.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akero Therapeutics Inc:

  • The EOD is 2.923. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.712. Based on the equity, the company is underpriced. +1
  • The TTM is 2.473. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.923MRQ2.712+0.211
MRQ2.712TTM2.473+0.239
TTM2.473YOY7.943-5.470
TTM2.4735Y7.413-4.940
5Y7.41310Y5.992+1.421
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9231.979+0.944
MRQ2.7122.051+0.661
TTM2.4732.365+0.108
YOY7.9432.455+5.488
5Y7.4133.726+3.687
10Y5.9924.378+1.614
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akero Therapeutics Inc.

4.8.1. Institutions holding Akero Therapeutics Inc

Institutions are holding 105.398% of the shares of Akero Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Wellington Management Company LLP11.31340.03977896632278202954.3938
2024-09-30HHG PLC10.13980.103970774782012252.9264
2024-09-30RTW INVESTMENTS, LLC8.48072.457359194354874508.9737
2024-06-30BlackRock Inc8.00390.003558663769402114.1851
2024-09-30General Atlantic Llc7.49864.2691523398900
2024-09-30T. Rowe Price Associates, Inc.5.45620.01263808359-337992-8.1516
2024-09-30Vanguard Group Inc5.26740.00193676581-28509-0.7695
2024-09-30Alkeon Capital Management, LLC4.76370.16353325004-2216-0.0666
2024-09-30State Street Corp3.58590.00292502946-186480-6.9338
2024-09-30AllianceBernstein L.P.2.88980.019420170881092315.7253
2024-09-30Perceptive Advisors LLC2.45681.0408171480621490914.3283
2024-09-30Boxer Capital LLC2.40222.3607167673300
2024-09-30Geode Capital Management, LLC2.25080.00371571012-48027-2.9664
2024-09-30Redmile Group, LLC1.98782.34511387479-226994-14.0599
2024-09-30Point72 Asset Management, L.P.1.86720.095130332313033230
2024-09-30T. Rowe Price Investment Management,Inc.1.86260.02251300096-467147-26.4337
2024-09-30Baker Bros Advisors LP1.57180.3262109708200
2024-09-30Rock Springs Capital Management LP1.33730.8712933399-140862-13.1125
2024-09-30Logos Global Management LP1.14612.4764800000-800000-50
2024-09-30Yiheng Capital LLC1.08711.1178758769-675410-47.0938
Total 85.369117.732759586848+2878551+4.8%

4.9.2. Funds holding Akero Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Health Care Inv6.30550.259344011682858133185.228
2024-09-30Janus Henderson Global Life Sciences2.88511.01022013792-118086-5.5391
2024-09-30Janus Henderson Global Life Sciences D2.88511.01352013792-26020-1.2756
2024-10-31Vanguard Total Stock Mkt Idx Inv2.75960.00341926204-14722-0.7585
2024-11-27iShares Russell 2000 ETF2.69950.07521884238-3934-0.2083
2024-09-30US Small-Cap Growth II Equity Comp2.59940.24461814384-181251-9.0824
2024-09-30T. Rowe Price New Horizons2.59940.24461814384-5717-0.3141
2024-09-30Janus Global Life Science AUSD2.14211.0041495191-51080-3.3034
2024-10-31Janus Henderson Glb Life Scn I2 USD1.96071.00681368570-126621-8.4686
2024-11-27SPDR® S&P Biotech ETF1.41940.4294990742-30060-2.9447
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.36950.0272955892-2774-0.2894
2024-09-30Fidelity Small Cap Index0.98710.072688960-4576-0.6598
2024-09-30T. Rowe Price Health Sciences0.87210.113608731-12141-1.9555
2024-09-30AB Small Cap Growth A0.80250.4185560134148102.7158
2024-11-27iShares Russell 2000 Value ETF0.79430.12795544107160.1293
2024-10-31Wellington Global Hlthcr Eq USD G Ac0.65030.6181453903-80725-15.0993
2024-09-30T. Rowe Price Small-Cap Value0.62610.1155436978-13463-2.9888
2024-09-30T. Rowe Price New Horizons Tr-Z0.60860.24542481564511.542
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.59760.0286417085-13900-3.2252
2024-11-27iShares Biotechnology ETF0.5720.18433992784060.1018
Total 36.13597.241125222651+2195446+8.7%

5.3. Insider Transactions

Insiders are holding 5.343% of the shares of Akero Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-02Andrew ChengSELL2500032.09
2024-12-02Jonathan YoungSELL1000032.13
2024-11-15Catriona YaleSELL906127.73
2024-11-01Andrew ChengSELL10836631.73
2024-11-01Catriona YaleSELL1548532.62
2024-11-01Jonathan YoungSELL5071631.57
2024-10-30Catriona YaleSELL451532.53
2024-10-18Andrew ChengSELL6353931.53
2024-10-16Andrew ChengSELL2499231.14
2024-10-14Jonathan YoungSELL4000030.15
2024-10-14Catriona YaleSELL613630.03
2024-10-01Jonathan YoungSELL1000028.18
2024-09-20Catriona YaleSELL550027.65
2024-09-18Catriona YaleSELL387127.56
2024-09-16Catriona YaleSELL248527.52
2024-09-10William Richard WhiteSELL63926.18
2024-09-10Jonathan YoungSELL56826.18
2024-09-10Andrew ChengSELL173826.18
2024-09-10Catriona YaleSELL63726.18
2024-08-26William Richard WhiteSELL7515927.21
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets817,547
Total Liabilities79,222
Total Stockholder Equity738,325
 As reported
Total Liabilities 79,222
Total Stockholder Equity+ 738,325
Total Assets = 817,547

Assets

Total Assets817,547
Total Current Assets746,888
Long-term Assets70,659
Total Current Assets
Cash And Cash Equivalents 316,065
Short-term Investments 401,182
Other Current Assets 29,641
Total Current Assets  (as reported)746,888
Total Current Assets  (calculated)746,888
+/-0
Long-term Assets
Property Plant Equipment 835
Long Term Investments 69,824
Long-term Assets  (as reported)70,659
Long-term Assets  (calculated)70,659
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities43,291
Long-term Liabilities35,931
Total Stockholder Equity738,325
Total Current Liabilities
Short-term Debt 631
Accounts payable 25,223
Other Current Liabilities 17,437
Total Current Liabilities  (as reported)43,291
Total Current Liabilities  (calculated)43,291
+/-0
Long-term Liabilities
Long term Debt 35,123
Capital Lease Obligations Min Short Term Debt605
Long-term Liabilities  (as reported)35,931
Long-term Liabilities  (calculated)35,728
+/- 203
Total Stockholder Equity
Common Stock7
Retained Earnings -756,132
Accumulated Other Comprehensive Income 2,103
Other Stockholders Equity 1,492,347
Total Stockholder Equity (as reported)738,325
Total Stockholder Equity (calculated)738,325
+/-0
Other
Capital Stock7
Cash and Short Term Investments 717,247
Common Stock Shares Outstanding 69,442
Liabilities and Stockholders Equity 817,547
Net Debt -279,706
Net Invested Capital 773,448
Net Working Capital 703,597
Property Plant and Equipment Gross 835
Short Long Term Debt Total 36,359



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
658
0
0
0
77,151
72,066
163,168
150,143
138,118
126,621
114,058
300,036
273,339
257,623
238,009
223,533
195,548
169,887
185,675
379,408
356,570
348,818
663,806
635,331
580,271
912,243
865,043
817,547
817,547865,043912,243580,271635,331663,806348,818356,570379,408185,675169,887195,548223,533238,009257,623273,339300,036114,058126,621138,118150,143163,16872,06677,151000658
   > Total Current Assets 
638
0
0
0
77,131
70,699
163,108
150,073
138,049
126,218
113,193
298,033
271,345
255,776
236,222
221,807
193,582
167,934
184,147
377,946
355,173
347,489
643,203
575,979
559,962
911,280
776,010
746,888
746,888776,010911,280559,962575,979643,203347,489355,173377,946184,147167,934193,582221,807236,222255,776271,345298,033113,193126,218138,049150,073163,10870,69977,131000638
       Cash And Cash Equivalents 
598
0
0
0
75,975
69,796
162,654
147,835
136,400
47,245
63,247
192,679
187,242
187,960
157,538
164,935
150,483
150,489
177,727
374,003
249,773
257,884
444,156
269,546
234,207
623,854
310,355
316,065
316,065310,355623,854234,207269,546444,156257,884249,773374,003177,727150,489150,483164,935157,538187,960187,242192,67963,24747,245136,400147,835162,65469,79675,975000598
       Short-term Investments 
0
0
0
0
0
0
0
0
71,612
78,040
39,586
99,191
81,145
62,024
72,490
50,146
37,775
14,887
2,998
0
101,676
85,338
195,288
285,186
315,803
279,811
449,839
401,182
401,182449,839279,811315,803285,186195,28885,338101,67602,99814,88737,77550,14672,49062,02481,14599,19139,58678,04071,61200000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
201
115
115
114
417
0
0
0
0
0
0
0
0
0
0
0
00000000000417114115115201000000000000
       Other Current Assets 
0
0
0
0
1,156
903
454
2,238
1,649
933
10,360
6,163
2,958
5,792
6,194
6,726
5,324
2,558
3,422
3,943
3,724
4,267
3,759
21,247
9,952
7,615
15,816
29,641
29,64115,8167,6159,95221,2473,7594,2673,7243,9433,4222,5585,3246,7266,1945,7922,9586,16310,3609331,6492,2384549031,1560000
   > Long-term Assets 
0
0
0
0
20
1,367
60
70
69
403
865
2,003
1,994
1,847
1,787
1,726
1,966
1,953
1,528
1,462
1,397
1,329
20,603
59,352
20,309
963
89,033
70,659
70,65989,03396320,30959,35220,6031,3291,3971,4621,5281,9531,9661,7261,7871,8471,9942,0038654036970601,367200000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
226
0
1,847
1,793
1,732
1,672
1,612
1,549
1,485
1,420
1,354
1,289
1,221
1,152
1,088
1,026
963
900
835
8359009631,0261,0881,1521,2211,2891,3541,4201,4851,5491,6121,6721,7321,7931,8470226000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,451
58,264
19,283
0
88,133
69,824
69,82488,133019,28358,26419,4510000000000000000000000
       Long-term Assets Other 
0
0
0
0
20
1,367
60
70
69
177
865
156
201
115
115
114
417
468
108
108
108
108
0
0
0
0
0
0
0000001081081081084684171141151152011568651776970601,367200000
> Total Liabilities 
222
0
0
0
127,070
2,404
4,779
6,759
9,392
8,298
10,395
13,578
14,627
11,603
17,876
24,905
26,439
23,352
37,303
35,900
30,008
42,473
47,369
52,196
44,965
65,990
66,976
79,222
79,22266,97665,99044,96552,19647,36942,47330,00835,90037,30323,35226,43924,90517,87611,60314,62713,57810,3958,2989,3926,7594,7792,404127,070000222
   > Total Current Liabilities 
222
0
0
0
2,342
2,404
4,740
6,725
9,369
8,286
10,393
12,014
13,111
10,136
16,459
23,540
25,128
22,097
26,697
25,243
19,083
16,678
21,602
28,447
19,128
30,259
31,174
43,291
43,29131,17430,25919,12828,44721,60216,67819,08325,24326,69722,09725,12823,54016,45910,13613,11112,01410,3938,2869,3696,7254,7402,4042,342000222
       Short-term Debt 
0
0
0
0
0
0
0
0
0
230
0
303
294
337
227
199
205
212
255
303
325
410
493
2,581
522
640
629
631
6316296405222,5814934103253032552122051992273372943030230000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,076
0
0
0
0
00002,07600000000000000000000000
       Accounts payable 
60
0
0
0
1,373
952
3,248
93
947
1,535
2,536
4,636
3,428
4,605
2,307
6,784
6,706
4,450
6,877
6,010
7,968
7,080
10,121
11,454
7,038
13,783
14,568
25,223
25,22314,56813,7837,03811,45410,1217,0807,9686,0106,8774,4506,7066,7842,3074,6053,4284,6362,5361,535947933,2489521,37300060
       Other Current Liabilities 
0
0
0
0
969
1,452
1,492
6,632
8,422
126
7,857
7,075
9,389
5,194
13,925
16,557
18,217
17,435
19,565
18,930
10,790
9,188
11,481
14,917
11,568
15,836
15,977
17,437
17,43715,97715,83611,56814,91711,4819,18810,79018,93019,56517,43518,21716,55713,9255,1949,3897,0757,8571268,4226,6321,4921,4529690000
   > Long-term Liabilities 
0
0
0
0
124,728
952
39
34
23
12
2
1,564
1,516
1,467
1,417
1,365
1,311
1,255
10,606
10,657
10,925
25,795
25,767
23,749
25,837
35,731
35,802
35,931
35,93135,80235,73125,83723,74925,76725,79510,92510,65710,6061,2551,3111,3651,4171,4671,5161,564212233439952124,7280000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,366
9,447
9,541
24,616
0
0
0
0
0
0
00000024,6169,5419,4479,366000000000000000000
       Other Liabilities 
0
0
0
0
0
0
39
34
23
12
2
0
0
0
0
1,365
0
0
41
70
305
0
85
0
0
0
0
0
000008503057041001,3650000212233439000000
       Deferred Long Term Liability 
0
0
0
0
0
1,327
0
0
0
0
0
0
46
0
0
0
0
0
41
70
305
162
0
0
0
0
0
0
000000162305704100000460000001,32700000
> Total Stockholder Equity
-4,564
-4,564
0
0
-49,919
69,662
158,389
143,384
128,726
118,323
103,663
286,458
258,712
246,020
220,133
198,628
169,109
146,535
148,372
343,508
326,562
306,345
616,437
583,135
535,306
846,253
798,067
738,325
738,325798,067846,253535,306583,135616,437306,345326,562343,508148,372146,535169,109198,628220,133246,020258,712286,458103,663118,323128,726143,384158,38969,662-49,91900-4,564-4,564
   Common Stock
0
0
0
0
0
2
3
3
3
3
3
4
4
4
4
4
4
4
4
5
5
5
6
6
6
7
7
7
7776665554444444433333200000
   Retained Earnings -756,132-683,427-627,440-574,096-518,910-479,251-448,168-422,337-399,278-363,736-336,333-310,304-277,880-253,550-224,617-209,527-179,816-158,413-142,206-130,320-114,709-99,155-91,927-86,565000-4,564
   Capital Surplus 
0
0
0
0
36,646
36,861
257,541
258,090
259,049
260,481
0
0
468,238
470,635
473,688
476,521
479,436
482,894
512,107
742,781
748,857
754,487
0
0
0
0
0
0
000000754,487748,857742,781512,107482,894479,436476,521473,688470,635468,23800260,481259,049258,090257,54136,86136,6460000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
36,646
161,587
257,541
258,090
259,049
260,481
261,983
466,254
468,238
470,635
473,688
476,521
479,436
482,894
512,107
742,781
748,857
754,487
1,095,933
1,102,545
1,109,126
1,473,765
1,481,748
1,492,347
1,492,3471,481,7481,473,7651,109,1261,102,5451,095,933754,487748,857742,781512,107482,894479,436476,521473,688470,635468,238466,254261,983260,481259,049258,090257,541161,58736,6460000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-29
Gross Profit-29-29
 
Operating Income (+$)
Gross Profit-29
Operating Expense-172,870
Operating Income-172,870-172,899
 
Operating Expense (+$)
Research Development141,798
Selling General Administrative31,072
Selling And Marketing Expenses29
Operating Expense172,870172,899
 
Net Interest Income (+$)
Interest Income24,210
Interest Expense-3,099
Other Finance Cost-23,675
Net Interest Income-2,564
 
Pretax Income (+$)
Operating Income-172,870
Net Interest Income-2,564
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-151,759-193,981
EBIT - interestExpense = -151,759
-151,759
-148,660
Interest Expense3,099
Earnings Before Interest and Taxes (EBIT)-148,660-148,660
Earnings Before Interest and Taxes (EBITDA)-148,631
 
After tax Income (+$)
Income Before Tax-151,759
Tax Provision-0
Net Income From Continuing Ops-119,632-151,759
Net Income-151,759
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses172,870
Total Other Income/Expenses Net21,1112,564
 

Technical Analysis of Akero Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akero Therapeutics Inc. The general trend of Akero Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akero Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akero Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 33.30 < 35.36 < 35.78.

The bearish price targets are: 27.82 > 27.05 > 26.46.

Tweet this
Akero Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akero Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akero Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akero Therapeutics Inc. The current macd is 0.20138243.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akero Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Akero Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Akero Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Akero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAkero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akero Therapeutics Inc. The current adx is 16.43.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Akero Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Akero Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akero Therapeutics Inc. The current sar is 27.76.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Akero Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akero Therapeutics Inc. The current rsi is 48.79. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Akero Therapeutics Inc Daily Relative Strength Index (RSI) ChartAkero Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akero Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akero Therapeutics Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Akero Therapeutics Inc Daily Stochastic Oscillator ChartAkero Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akero Therapeutics Inc. The current cci is -44.22602164.

Akero Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAkero Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akero Therapeutics Inc. The current cmo is -7.39724167.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Akero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAkero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akero Therapeutics Inc. The current willr is -38.08.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Akero Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Akero Therapeutics Inc Daily Williams %R ChartAkero Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akero Therapeutics Inc.

Akero Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akero Therapeutics Inc. The current atr is 1.55853845.

Akero Therapeutics Inc Daily Average True Range (ATR) ChartAkero Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akero Therapeutics Inc. The current obv is -3,312,464.

Akero Therapeutics Inc Daily On-Balance Volume (OBV) ChartAkero Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akero Therapeutics Inc. The current mfi is 54.12.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Akero Therapeutics Inc Daily Money Flow Index (MFI) ChartAkero Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akero Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Akero Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.794
Ma 20Greater thanMa 5031.744
Ma 50Greater thanMa 10030.511
Ma 100Greater thanMa 20028.439
OpenGreater thanClose30.770
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akero Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Akero Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akero Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akero Therapeutics Inc

I send you an email if I find something interesting about Akero Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Akero Therapeutics Inc.

Receive notifications about Akero Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.